Section 2 - Summary of Safety and Effectiveness Ko 3 | a7 | {oF 2CHIN ¢ = STaTy ot pa —e Eee
This summary of the 510(k) pre-market notification for the Smith & Nephew Saphyre Bipolar
Ablation Probes is being submitted in accordance with the requirements of SMDA 1990 and 21
CFR 807.92, MAY 2 3 2003
Manufacturer Contact Person(s)
Smith & Nephew, Inc Deborah Connors
Endoscopy Division Smith & Nephew, Regulatory Affairs Manager
3700 Haven Court 150 Minuteman Road
Menlo Park, CA 94025 Andover, MA 01810
Device Name
Saphyre Bipolar Ablation Probes, Class I device (21 CFR 878.4400)
Generic/Common Name
Electrosurgical cutting and coagulation device and accessories
Device Description
The Smith & Nephew Saphyre Bipolar Ablation Probes are single-use, bipolar, electrosurgical
devices intended for coagulation of soft tissues. The Saphyre Bipolar Ablation Probes consist of
an insulated shaft, an insulated power electrode, a return electrode, and a handle. Saphyre
Bipolar Ablation Probes with Suction incorporate suction capability for the removal of tissue
from the surgical site.
Technological Characteristics
Smith & Nephew is requesting clearance to modify the device’s existing general indications for
use to more specific indications for use. There was no actual physical change to the device as a
result of the proposed modified indications for use statement and, therefore, no changes to the
technological characteristics.
Indications for Use
The Smith & Nephew Saphyre Bipolar Ablation Probes, in combination with the Smith &
Nephew Vuican EAS Generator, are intended for general surgical use, including orthopedic and
arthroscopic applications for resection, ablation, excision of soft tissue, hemostasis of blood
vessels, and in coagulating soft tissue in joints including but not limited to the knee, shoulder,
wrist, hip, etc. Arthroscopic surgery could include a variety of procedures.
.. ~ Piedicare Device(s)
¢ Indication for Use: Vulcan Electrosurgical Probes K000691, cleared May 15, 2000
ArthroCare ArthroWands K011083, cleared June 28, 2001
« Design: Bipolar Ablation Probes K991218, cleared September 13, 1999
Smith & Nephew Bipolar Ablation Probes Section 2
Specific Indications For Use Page 1 of 2

Section 2 - Summary of Safety and Effectiveness Ko 3)37) Zot

Substantial Equivalence Determination
The modified indications for use for the Smith & Nephew Saphyre Bipolar Ablation Probes are
substantially equivalent to the predicate devices. This determination is based on the following:
1. The indications for use, as modified for the Saphyre Bipolar Ablation Probes, and design are

equivalent to that of the predicate devices and;
2. No new risks have been introduced as a result of the modification.
‘Smith & Nephew Bipolar Ablation Probes. —=—=~=~S*~*~*~<“S*~“<~S*C‘“‘<S*tCStSSS Seti
Specific Indications For Use Page 2 of 2

ain
& DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service re
‘ & TT
Ne Food and Drug Administ?tion
9200 Corporate Boulevard
MAY 2 3 2003 Rockville MD 20850
Ms. Linda Guthrie
Manager Regulatory Affairs and Compliance
Smith & Nephew, Inc.
Endoscopy Division
3700 Haven Court
Menlo Park, California 94025
Re: K031371
Trade/Device Name: Smith & Nephew Saphyre Bipolar Ablation Probes
Regulation Number: 21 CFR 878.4400
Regulation Name: Electrosurgical cutting and coagulation device and accessories
Regulatory Class: II
Product Code: GEI
Dated: April 25, 2003 :
Received: April 30, 2003
Dear Ms. Guthrie:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class II (Special Controls) or class II] (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register. :
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 - Ms. Linda Guthrie
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the
promotion and advertising of your device, please contact the Office of Compliance at (301) 5944639. Also, please note the regulation entitled, "Misbranding by reference to premarket
notification” (21CFR Part 807.97) you may obtain. Other general information on your
responsibilities under the Act may be obtained from the Division of Small Manufacturers,
International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597
or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html .
Sincerely yours,
Jnurvan. C. Vreroot
£60 celia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health :
Enclosure .

MAY-16-2003 07:56AM — FROM-SMITH#NEPHEW MENLO PARK 650-687-2682 T-419 = P.003/007 —F-182
Section 1 - General Information . nen
_~.
INDICATIONS FOR USE STATEMENT
$10(kK) Number: K031371
Device Name: Smith & Nephew Saphyre Bipolar Ablation Probes
Indications for Use: | The Smith & Nephew Saphyre Bipolar Ablation Probes, in combination
with the Smith & Nephew Vulcan EAS Generator, are intended for genera!
surgical use, including orthopedic and arthroscopic applications for
resection, ablation, excision of soft tissue, hemostasis of blood vessels, and
and in coagulating soft tissue in joints including but not limited to the
knee, shoulder, wrist, hip, etc. Arthroscopic surgery could include a
variety of procedures, as listed in the table below.
Examples of Arthroscopic Surge!
All Joints Debridement (tendon, cartilage, fracture), Plica Removal, Resection, Synovectomy, |
Bursectomy, Ablation, Excision of Soft Tissue (scar tissue), Hemostasis of Blood
Vessels, Coagulating Soft Tissues (ligament, articular cartilage), and Chondroplasty.
Meniscectomy, Meniscal Cystectomy, PCL/ACL Debridement, Natchplasty, Lateral
Release, Labral Tear.
Shoulder Acromioplasty, Rotator Cup Debridement, Subacromial Decompression, CA Ligament
Resection, and Capsular Release.
Triangular Fibrocartilage (TFC).
Mw
o —
>
go
2 a 9 PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF
oo
23 SQ NEEDED
ea
O8s .
& 3 ‘3 8 Concurrence of CDRH, Office of Device Evaluation (ODE)
mawe €
oo 3
§e5 24
265 _ .
Baz erescription Use OR Over-The-Counter Use
A (2 | Ber 21 CFR 801.109)
Se ‘Smith & Nephew Bipolar Ablation Probes _—=«=S*CSConnfideraiel Information ~—=~=~*~<“<‘“‘=~*‘“‘~*S dC
Specific Indications For Use Page 4 of 4

